JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide
Abstract Cancer stem cells play an important role on tumor progression. Biomarkers of stem cell property and their relationship to extranodal involvement of malignant lymphocytes are undefined in diffuse large B-cell lymphoma (DLBCL). Here we showed that junctional adhesion molecule-A (JAM-A) was hi...
Enregistré dans:
Auteurs principaux: | Peng-Peng Xu, Yi-Feng Sun, Ying Fang, Qi Song, Zi-Xun Yan, Yi Chen, Xu-Feng Jiang, Xiao-Chun Fei, Yan Zhao, Christophe Leboeuf, Biao Li, Chao-Fu Wang, Anne Janin, Li Wang, Wei-Li Zhao |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8bcc11ed23b34a3a8a8f7e40828d481d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
par: Jia Li, et autres
Publié: (2021) -
CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis
par: Chen-xing Zhao, et autres
Publié: (2021) -
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
par: Julio Delgado, et autres
Publié: (2021) -
Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer.
par: Liang Ma, et autres
Publié: (2011) -
Therapy of Angiosarcoma with Thalidomide and Lenalidomide
par: M. Jules Mattes, et autres
Publié: (2021)